<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The pathogenesis of <z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon's syndrome</z:e> is unclear </plain></SENT>
<SENT sid="1" pm="."><plain>This study addresses the question whether cerebral <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> may be involved in the pathogenesis of the neurologic complications of the disorder </plain></SENT>
<SENT sid="2" pm="."><plain>The study consisted of 13 patients with <z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon's syndrome</z:e> defined by both generalized <z:hpo ids='HP_0000965'>livedo reticularis</z:hpo> and a history of one or more cerebrovascular ischemic events; none had clinical or Doppler ultrasonographic evidence of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Transcranial Doppler microembolic monitoring of the middle cerebral artery; blood screening for <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (<z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, anticardiolipin antibodies) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Five patients (38%) showed clinically silent microembolism at transcranial Doppler monitoring, with individual microembolic event rates of the middle cerebral artery between 2 per hour and 33 per hour </plain></SENT>
<SENT sid="5" pm="."><plain>In this group, the time since the last ischemic symptom was significantly shorter than in the eight patients without microemboli </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> were detected in three patients (23%), <z:hpo ids='HP_0000001'>all</z:hpo> of whom belonged to the microemboli-positive group </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: These data suggest that the detectability of both clinically silent cerebral microembolism and <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> may provide paraclinical evidence of active disease in patients with <z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon's syndrome</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The results support the notion that an immune-mediated prothrombotic state facilitating the formation of arterial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> with subsequent cerebral embolization, and/or triggering in situ <z:mp ids='MP_0005048'>thrombosis</z:mp> of cerebral vessels, plays a pathogenetic role in the neurologic manifestations of this disorder </plain></SENT>
</text></document>